A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Antidiabetic Drugs Added to Metformin in Patients with Type 2 Diabetes

被引:0
作者
Huang, Huan [3 ]
Bell, Kelly F. [1 ]
Gani, Ray [2 ]
Tugwell, Cathy W. [1 ]
Eudicone, James M. [1 ]
Krukas-Hampel, Michelle R. [3 ]
机构
[1] AstraZeneca, Wilmington, DE USA
[2] IQVIA, Reading, Berks, England
[3] IQVIA, Cambridge, England
关键词
INADEQUATE GLYCEMIC CONTROL; ADD-ON THERAPY; PLACEBO-CONTROLLED TRIAL; MEDICAL-RECORD DATABASE; DOUBLE-BLIND; BLOOD-PRESSURE; BODY-WEIGHT; UNITED-STATES; FAT MASS; MONOTHERAPY;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: The efficacy of dapagliflozin as add-on therapy to metformin has been assessed in randomized trials. However, its effectiveness has not been assessed in a US real-world setting. Methods: Electronic medical record (EMR) data were used to compare clinical outcomes among patients with type 2 diabetes (T2D) treated with dapagliflozin and metformin with or without other oral antidiabetic drugs (D + M +/- OAD), versus metformin with at least 1 other OAD (M + OAD). Adult patients with T2D on these regimens from January 01, 2014, to February 28, 2015, were identified in a US EMR database, with the date of first prescription for dapagliflozin (D + M +/- OAD) or other OAD (M + OAD) as the index date. Patients were observed for 12 months before the index date (baseline) and 12 months afterward (ie, follow-up). Patients in the M + OAD group were propensity score matched 1: 1 to those in the D + M +/- OAD group. Outcomes included change in glycated hemoglobin (A1C) level, weight, and systolic and diastolic blood pressures (SBP/DBP) from baseline to follow-up. Results: A total of 1093 patients receiving M + OAD were matched to 1093 patients receiving D + M +/- OAD. Compared with those given M + OAD, patients given D + M +/- OAD had a greater reduction in A1C level (mean, -1.0% vs -0.7%; P <. 01), greater weight loss (-1.8 kg vs -0.7 kg, P <. 01), and greater change in SBP (-3.6 mm Hg vs -0.1 mm Hg, P <. 01) and DBP (-2.0 mm Hg vs -0.6 mm Hg, P <. 01) from baseline to follow-up. Conclusions: In current US clinical practice, patients receiving D + M +/- OAD had greater reductions in important clinical outcomes of T2D-A1C level, weight loss, and blood pressure-versus patients receiving M + OAD. This study supports the use of dapagliflozin as add-on therapy to metformin with or without other OADs for patients with T2D.
引用
收藏
页码:S132 / S137
页数:6
相关论文
共 23 条
  • [1] [Anonymous], 2018, DIABETES CARE, V41, pS1, DOI [10.2337/dc18-SINT01, 10.2337/dc18-Sint01]
  • [2] Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
    Bailey, Clifford J.
    Gross, Jorge L.
    Pieters, Anne
    Bastien, Arnaud
    List, James F.
    [J]. LANCET, 2010, 375 (9733) : 2223 - 2233
  • [3] Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
    Bolinder, J.
    Ljunggren, O.
    Johansson, L.
    Wilding, J.
    Langkilde, A. M.
    Sjostrom, C. D.
    Sugg, J.
    Parikh, S.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (02) : 159 - 169
  • [4] Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
    Bolinder, Jan
    Ljunggren, Osten
    Kullberg, Joel
    Johansson, Lars
    Wilding, John
    Langkilde, Anna Maria
    Sugg, Jennifer
    Parikh, Shamik
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (03) : 1020 - 1031
  • [5] The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients
    Charlson, Mary E.
    Charlson, Robert E.
    Peterson, Janey C.
    Marinopoulos, Spyridon S.
    Briggs, William M.
    Hollenberg, James P.
    [J]. JOURNAL OF CLINICAL EPIDEMIOLOGY, 2008, 61 (12) : 1234 - 1240
  • [6] Prevalence of Obesity, Type II Diabetes Mellitus, Hyperlipidemia, and Hypertension in the United States: Findings from the GE Centricity Electronic Medical Record Database
    Crawford, Albert G.
    Cote, Christine
    Couto, Joseph
    Daskiran, Mehmet
    Gunnarsson, Candace
    Haas, Kara
    Haas, Sara
    Nigam, Somesh C.
    Schuette, Rob
    [J]. POPULATION HEALTH MANAGEMENT, 2010, 13 (03) : 151 - 161
  • [7] Comparison of GE Centricity Electronic Medical Record Database and National Ambulatory Medical Care Survey Findings on the Prevalence of Major Conditions in the United States
    Crawford, Albert G.
    Cote, Christine
    Couto, Joseph
    Daskiran, Mehmet
    Gunnarsson, Candace
    Haas, Kara
    Haas, Sara
    Nigam, Somesh C.
    Schuette, Rob
    Yaskin, Joseph
    [J]. POPULATION HEALTH MANAGEMENT, 2010, 13 (03) : 139 - 150
  • [8] Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data
    Del Prato, S.
    Nauck, M.
    Duran-Garcia, S.
    Maffei, L.
    Rohwedder, K.
    Theuerkauf, A.
    Parikh, S.
    [J]. DIABETES OBESITY & METABOLISM, 2015, 17 (06) : 581 - 590
  • [9] Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
    Ferrannini, Ele
    Jimenez Ramos, Silvia
    Salsali, Afshin
    Tang, Weihua
    List, James F.
    [J]. DIABETES CARE, 2010, 33 (10) : 2217 - 2224
  • [10] CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM-2018 EXECUTIVE SUMMARY
    Garber, Alan J.
    Abrahamson, Martin J.
    Barzilay, Joshua I.
    Blonde, Lawrence
    Bloomgarden, Zachary T.
    Bush, Michael A.
    Dagogo-Jack, Samuel
    DeFronzo, Ralph A.
    Einhorn, Daniel
    Fonseca, Vivian A.
    Garber, Jeffrey R.
    Garvey, W. Timothy
    Grunberger, George
    Handelsman, Yehuda
    Hirsch, Irl B.
    Jellinger, Paul S.
    McGill, Janet B.
    Mechanick, Jeffrey I.
    Rosenblit, Paul D.
    Umpierrez, Guillermo E.
    [J]. ENDOCRINE PRACTICE, 2018, 24 (01) : 91 - 120